drugset / Trial / NCT06641180
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.
Timeline
- Start
- 2024-11-04
- Primary completion
- 2025-01-28
- Completion
- 2025-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | High-Dose trivalent influenza vaccine (Split virion, Inactivated) | Vaccine | — | Intramuscular |
| Comparator | Standard-dose trivalent influenza vaccine (Split virion, Inactivated) | Vaccine | — | Intramuscular |